Cytokines in leprosy, I. Serum cytokine profile in leprosy

International Journal of Dermatology

Volumn 37, Issue 10, 1998, Pages 733-740

  Moubasher, Alaa El Din A ^a   Kamel, Neveen A ^a   Zedan, Hatem ^a   Raheem, Diaa El Din Abdel ^a  

^a Assiut University Faculty of Medicine   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELLULAR IMMUNITY; CHRONIC DISEASE; CONTROLLED STUDY; HUMAN; IMMUNE COMPLEX DISEASE; LEPROSY; MAJOR CLINICAL STUDY; MYCOBACTERIUM LEPRAE;

CYTOKINES; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-2; LEPROSY; LEPROSY, BORDERLINE; LEPROSY, LEPROMATOUS; LEPROSY, TUBERCULOID; MALE; RECEPTORS, INTERLEUKIN-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031662934     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1998.00381.x     Document Type: Article

References (68)

1. Harboe M. Overview of host-parasite relations. In: Hastings RC, Opromolla DVA, eds. Leprosy, 2nd edn. Edinburgh, New York: Churchill Livingstone, 1994: 87-112.
2. Browne SG. Acta Clinica Leprosy, 1st edn. Basle, Switzerland: Ciba-Geigy Ltd, 1976: 52-56.
3. Ramos T, Quintana IZ, Appelberg R, et al. T-helper cell subpopulations and the immune spectrum of leprosy. Int J Lepr 1989; 57: 73-81.
4. Volc-Platzer B, Stemberger H, Luger T, et al. Defective intralesional interferon-gamma activity in patients with lepromatous leprosy. Clin Exp Immunol 1988; 71: 235-240.
5. Arnoldi J, Gerdes J, Flad HD. Immunohistologic assessment of cytokine production of infiltrating cells in various forms of leprosy. Am J Pathol 1990; 137: 749-753.
6. Yamamura M, Uyemura K, Deans RJ, et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277-279.
7. Jopling WH. Classification of reactions in leprosy (Letter). Lepr Rev 1970; 41: 62-63.
8. Godal T, Myrvang B, Samuel DR, et al. Mechanism of 'reactions' in borderline tuberculoid (BT) leprosy. Acta Path Microbiol Scand 1973; 236: 45-53.
9. Wemambu SNC, Turk JL, Waters MFR, et al. Erythema nodosum leprosum: a clinical manifestation of the Arthus phenomenon. Lancet 1969; 11: 933-935.
10. Modlin RL, Bakke AC, Vaccaro SA, et al. Tissue and blood T-lymphocyte subpopulations in erythema nodosum leprosum. Arch Dermatol 1985; 121: 216-219.
11. Beutler B, Cerami A. Cachectin; more than a tumor necrosis factor. N Engl Med 1987; 316: 379-385.
12. Grau GE, Roux-Lombard P, Gysler C, et al. Serum cytokine changes in systemic vasculitis. Immunology 1989; 68: 196-198.
13. Scollard DM. Inside the skin: the local immune and inflammatory milieu in leprosy. Am J Trop Med Hyg 1991; 44: 17-23
14. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr 1966; 34: 255-273.
15. Ridley DS, Hilson GRF. A logarithmic index of bacilli in biopsies, 1. Method Int J Lepr 1967; 35: 184-193.
16. Waters MFR, Rees RJW. Changes in the morphology of Mycobacterium leprae in patients under treatment. Int J Lepr 1962; 30: 266-277.
17. Ridley DS. Histological classification and the immunological spectrum of leprosy. Bull WHO 1974; 51: 451-465.
18. Sieling PA, Modlin RL. Cytokine patterns at the site of mycobacterial infection. Immunobiol 1994; 191: 378-387.
19. Ottenhoff THM, Converse PJ, Geber N, et al. T cell responses to fractionated Mycobacterium leprae antigens in leprosy. The lepromatous non-responder defect can be overcome in vitro by stimulation with fractionated Mycobacterium leprae components. Eur J Immunol 1989; 19: 707-713.
20. Haanen JBAG, de Waal Malefyt R, Res PCM, et al. Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med 1991; 174: 583-592.
21. Nogueira N, Kaplan G, Levy E, et al. Defective gamma interferon production in leprosy. Reversal with antigen and interleukin 2. J Exp Med 1983; 158: 2165-2170.
22. Shinde SR, Chiplunkar SV, Butlin R, et al. Lymphocyte proliferation, IFN-γ production and limiting dilution analysis of T-cell responses to ICRC and Mycobacterium leprae antigens in leprosy patients. Int J Lepr 1993; 61: 51-58.
23. Follows GA, Munk ME, Gatrill AJ, et al. Interferon γ and IL-2 but no IL-4 in γ-δ T cell cultures after activation with bacteria. Infect Immun 1992; 60: 1229-1231.
24. Kaplan G, Cohn ZA. Leprosy and cell-mediated immunity. Curr Opin Immunol 1991; 3: 91-96.
25. SivaSai KSR, Prasad HK, Misra RS, et al. Effect of recombinant Interferon gamma administration on lesional monocytes/macrophages in lepromatous leprosy patients. Int J Lepr 1993; 61: 259-269.
26. Barnes PF, Chatterjee D, Brennan PJ, et al. Tumor necrosis factor production in patients with leprosy. Infect Immun 1992; 60: 1441-1446.
27. Scuderi P, Lam KS, Ryan KJ, et al. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet 1986; 13: 1364-1365.
28. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988; 56: 2563-2569.
29. Bromberg JS, Chavin KD, Kunkel SL. Anti-tumor necrosis factor antibodies suppress cell-mediated immunity in vivo. J Immunol 1992; 148: 3412-3417.
30. Kindler V, Sappino AP, Grau GE, et al. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-740.
31. Silva CL, Foss NT. Tumor necrosis factor in leprosy patients. J Infect Dis 1989; 159: 787-792.
32. Parida SK, Grau GE, Zaheer SA, et al. Serum tumor necrosis factor and interleukin 1 in leprosy and during lepra reactions. Clin Immunol Immunopathol 1991; 63: 23-27.
33. Salgame PR, Abrams JS, Clayberger C, et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254: 279-282.
34. de Kossodo S, Grau GE. Profiles of cytokine production in relation with susceptibility to cerebral malaria. J Immunol 1993; 151: 4811-4820.
35. + T cell clones from blood and skin lesions of leprosy patients. Identification of T cell clones distinct from Th 0, Th 1 and Th 2. Immunology 1995; 84: 585-594.
36. Wilson CB, Westall J. Activation of neonatal and adult human macrophages by alpha, beta, and gamma interferons. Infect Immun 1985; 49: 351-356.
37. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138-146.
38. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Ann Rev Immunol 1993; 11: 571-611.
39. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. TH2 clones secrete a factor that inhibits cytokine production by TH1 clones. J Exp Med 1989; 170: 2081-2095.
40. Goodman JW. The immune response. In: Stites DP, Terr AI, Parslow TG, eds. Basic and Clinical Immunology, 8th edn. Norwalk, Connecticut: Appleton & Lange, 1994: 40-49.
41. Tung KSK, Umland E, Matzner P, et al. Soluble serum interleukin 2 receptor levels in leprosy patients. Clin Exp Immunol 1987; 68: 10-15.
42. Sehgal VN, Bhattacharya SN, Shan Y, et al. Soluble interleukin-2 receptors: levels in leprosy and during and after type 1 (lepra) and type 2 (ENL) reactions. Lepr Rev 1991; 62: 262-268.
43. Fafutis MM, Mejia SA, Gonzalez AM. Detection of interleukin-2 receptor (IL-2R) by indirect immunofluorescence with anti-Tac monoclonal antibody on the surface of lymphocytes from patients with lepromatous leprosy. Int J Lepr 1990; 58: 126-128.
44. Modlin RL, Hofman FM, Horwitz DA, et al. In situ identification of cells in human leprosy granulomas with monoclonal antibodies to interleukin 2 and its receptor. J Immunol 1984; 132: 3085-3090.
45. Waldmann TA. The IL-2/lL-2R system: a target for rational immune intervention. Immunol Today 1993; 14: 264-270.
46. Arai K, Lee F, Miyajima A, et al. Cytokines; coordinators of immune and inflammatory responses. Ann Rev Biochem 1990; 59: 783-836.
47. Sharma VK, Saha K, Sehgal VN. Serum immunoglobulins and autoantibodies during and after ENL. Int J Lepr 1981; 50: 159-163.
48. Dhar S, Kanwar AJ, Kaur S. Autoaggressive lepromatous leprosy. Int J Lepr 1993; 61: 467-468.
49. Smith KA, Lachman LB, Oppenheim JJ et al. The functional relationship of the interleukins. J Exp Med 1980; 151: 1551-1556.
50. Frei K, Nodal D, Pfister HW, et al. Listeria meningitis: identification of a cerebrospinal fluid inhibitor of macrophage listericidal function as interleukin 10. J Exp Med 1993; 178: 1255-1161.
51. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404-410.
52. Suzuki K, Fukutomi Y, Matsuoka M, et al. Differential production of interleukin 1 (IL-1), IL-6, tumor necrosis factor, and IL-1 receptor antagonist by human monocytes stimulated with Mycobacterium leprae and Mycobacterium bovis BCG. Int J Lepr 1993; 61: 609-618.
53. de Waal Malefyt R, Abrams J, Bennett B, et al. IL-10 inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209-1220.
54. Browne SG. Acta Clinica Leprosy, 3rd edn. Basle, Switzerland: Ciba-Geigy Ltd, 1984: 31-32.
55. Pearson JMH. Reactions In leprosy and immunological features of leprosy. In: Essentials of Leprosy, 4th edn. German Leprosy Relief Association, 1986: 16-20.
56. Yamamura M, Wong XH, Ohmen JD, et al. Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992; 149: 1470-1475.
57. Scollard DM, Suriyanon V, Bhoopat L, et al. Studies of human leprosy lesions in situ using suction-induced blisters, 2. Cell changes and soluble interleukin 2 receptor (Tac peptide) in reversal reactions. Int J Lepr 1990; 58: 469-479.
58. Dower SK, Kronheim SR, March CJ, et al. Detection and characterization of high affinity plasma membrane receptors for human interleukin 1. J Exp Med 1985; 162: 501-515.
59. Cooper CL, Muelier C, Sinchaisri TA, et al. Analysis of naturally occurring delayed type hypersensitivity reactions in leprosy by in situ hybridization. J Exp Med 1989; 169: 1565-1581.
60. Rea TH, Modlin RL. Immunopathology of leprosy skin lesions. Semin Dermatol 1991; 10: 188-193.
61. Naafs B. Leprosy reactions. Trop Geog Med 1994; 46: 80-84.
62. Defrance T, Vanbervliet B, Briere F, et al. Interleukin 10 and transforming growth factor-β cooperate to induce anti-CD40 activated native human B cells to secrete immunoglobulin A. J Exp Med 1992; 175: 671-682.
63. Ridley MJ, Ridley DS. The immunopathology of ENL: the role of extravascular complexes. Lepr Rev 1983; 54: 95-107.
64. Dahl MV. Interleukins and other cytokines. In: Clinical Immunodermatology, 3rd edn. St Louis/London: Mosby Year Book Inc, 1996: 87-97.
65. Lipsky PE, Thompson PA, Rosenwasser LJ, et al. The role of interleukin 1 in human B cell activation: inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen. J Immunol 1983; 130: 2708-2714.
66. Modlin RL. Thi-Th 2 paradigm: insights from leprosy. J Invest Dermatol 1994; 102: 828-832.
67. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-1652.
68. Lever WF, Schaumburg-Lever G. Leprosy. In: Histopathology of the Skin, 7th edn. Philadelphia/London/New York: JB Lippincott Co, 1990: 333-339.